CareDx, Inc., a leading precision medicine company, announced several key resolutions following a recent board meeting. The Board of Directors approved a new $50 million share repurchase program, aiming to buy back up to 5% of outstanding shares over the next 24 months. This decision follows the successful completion of a previous $50 million repurchase, highlighting the company's commitment to returning value to shareholders. The repurchase will be conducted at the company's discretion through various means, contingent on market conditions and other factors. The company also reported its seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, marking an 18% year-over-year increase. CareDx remains financially robust, ending the first quarter with $231 million in cash, cash equivalents, marketable securities, and no debt. CEO John W. Hanna expressed confidence in achieving long-term growth targets, including $500 million in revenue and 20% adjusted EBITA by 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.